Higher frequency of secretor phenotype in O blood group - its benefits in prevention and/or treatment of some diseases

International Journal of Nanomedicine

Volumn 5, Issue 1, 2010, Pages 901-905

  Jaff, Mohamad Salih ^a  

^a SALAHADDIN UNIVERSITY   (Iraq)

Author keywords

ABO blood groups; Blood group O; Frequency; Malignancies; Prevention and or treatment; Secretor phenotype

Indexed keywords

BLOOD GROUP ABH ANTIGEN;

ADULT; ARTICLE; BLOOD GROUP A; BLOOD GROUP AB; BLOOD GROUP ABO SYSTEM; BLOOD GROUP B; BLOOD GROUP LEWIS SYSTEM; BLOOD GROUP O; BLOOD SAMPLING; FEMALE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; MALE; NORMAL HUMAN; SALIVA ANALYSIS; SEX DIFFERENCE; BACTERIAL INFECTION; BLOOD; BLOOD GROUP RHESUS SYSTEM; CLASSIFICATION; GENE FREQUENCY; GENETICS; IMMUNOLOGY; MIDDLE AGED; NEOPLASM; PHENOTYPE; SALIVA; SECRETION;

ABO BLOOD-GROUP SYSTEM; ADULT; BACTERIAL INFECTIONS; FEMALE; GENE FREQUENCY; HUMANS; LEWIS BLOOD-GROUP SYSTEM; MALE; MIDDLE AGED; NEOPLASMS; PHENOTYPE; RH-HR BLOOD-GROUP SYSTEM; SALIVA; YOUNG ADULT;

EID: 79952118212     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S13980     Document Type: Article

References (41)

1. Watkins WM. The ABO blood group system: historical background. Transfus Med. 2001;11(4):243-265.
2. Henry SM. The biosynthetic pathway for blood group related glycoconjugates in the human gastrointestinal tract; a map of pathogen receptors and insights into ABO. Paper Presented at NZIMLS Annual Scientific Meeting; 2001; Auckland, New Zealand.
3. Jaff MS, O'Briain DS. Excess of blood group B in primary myelofibrosis. Vox Sang. 1987;52(3):250-253.
4. D'Adamo PJ, Kelly GS. Metabolic and immunologic consequences of ABH secretor and Lewis subtype status. Altern Med Rev. 2001;6(4): 390-405.
5. Slomiany BL, Slomiany A. ABH-blood-group antigens and glycolipid of human saliva. Eur J Biochem. 1978;85(1):249-254.
6. Greenwell P. Blood group antigens: molecules seeking a function? Glycoconj J. 1997;14(2):159-173.
7. Henry SM. Review: phenotyping for Lewis and secretor histo-blood group antigens. Immunohaematology. 1996;12:51-61.
8. Daniels G. Human Blood Groups. 2nd ed. Oxford (UK): Blackwell Science; 2002:7-70.
9. Henry S, Oriol R, Samuelsson B. Lewis histo-blood group system and associated secretory phenotypes. Vox Sang. 1995;69(3):166-182.
10. Henry S, Benny A, Woodsfield D. Investigation of Lewis phenotypes in Polynesians: evidence for a weak secretor phenotype. Vox Sang. 1990; 58(1):61-66.
11. Jaff MS, Bilbas FAH. Frequency of the ABH blood group antigen secretors among kurds. Zanco J Med Sci. 2007;11(2):15-19.
12. Race RR, Sanger R. Blood Groups in Man. 6th ed. Oxford (UK): Blackwell; 1975:323-349.
13. Meeran K, Bloom SR. Lewis phenotypes, insulin resistance, and risk of ischemic heart disease (editorial). Br Heart J. 1994;71(4):305-306.
14. Harmening DM. Modern Blood Banking and Transfusion Practices. 4th ed. Philadelphia (PA): F.A. Davis Company; 1999:90-158.
15. de Mattos LC, Cintra JR, Sanches FE, AlvesdaSilvaRde C, Ruiz MA, Moreira HW. ABO, Lewis, secretor and non-secretor phenotypes in patients infected or uninfected by the Helicobacter pylori bacillus. Sao Paulo Med J. 2002;120(2):55-58.
16. Garratty G. Blood groups and disease: a historical perspective. Transfus Med Rev. 2000;14(4):291-301.
17. Sharara AI, Abdul-Baki H, El-Hajj I, Kreidieh N, Kfoury Baz EM. Association of gastroduodenal disease phenotype with ABO blood group and helicobacter pylori virulence-specific serotypes. Dig Liver Dis. 2006;38(11):829-833.
18. Campi C, Escovich L, Valdés V, et al. Secretor status and ABH antigens expression in patients with oral lesions. Med Oral Patol Oral Cir Bucal. 2007;12(6):E431-E434.
19. Dabelsteen E, Gao S. ABO blood-group antigens in oral cancer. J Dent Res. 2005;84(1):21-28.
20. Roots I, Drakoulis N, Ploch M, et al. Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk. Klin Wochenschr. 1988;66 Suppl 11: 87-97.
21. Roberts TE, Hasleton P, Swindell R, Lawson R. Blood groups and lung cancer. Br J Cancer. 1988;58(2):278.
22. Fujitani N, Liu Y, Toda S, Shirouzu K, Okamura T, Kimura H. Expression of H type 1 antigen of ABO histo-blood group in normal colon and aberrant expressions of H type 2 and H type 3/4 antigens in colon cancer. Glycoconj J. 2000;17(5):331-338.
23. Henderson J, Seagroatt V, Goldacre M. Ovarian cancer and ABO blood groups. J Epidemiol Community Health. 1993;47(4):287-289.
24. Vioque J, Walker AM. Pancreatic cancer and ABO blood types: a study of cases and controls. Med Clin (Barc). 1991;96(20):761-764.
25. Wolpin BM, Kraft P, Gross M, et al. Pancreatic cancer risk and ABO blood group alleles: results from the Pancreatic Cancer Cohort Consortium. Cancer Res. 2009;70(3):1015-1023.
26. Oishi K, Okada K, Yoshida O, et al. Case-control study of prostatic cancer in Kyoto, Japan: demographic and some lifestyle risk factors. Prostate. 1989;14(2):117-122.
27. Nakata S, Sato J, Ohtake N, Imai K, Yamanaka H. Epidemiological study of risk factors for bladder cancer. Hinyokika Kiyo. 1995; 41(12):969-977.
28. Anderson DE, Haas C. Blood type A and familial breast cancer. Cancer. 1984;54(9):1845-1849.
29. Janardhana V, Propert DN, Green RE. ABO blood groups in hematologic malignancies. Cancer Genet Cytogenet. 1991;51(1):113-120.
30. Beckman L, Angqvist KA. On the mechanism behind the association between ABO blood groups and gastric carcinoma. Hum Hered. 1987; 37(3):140-143.
31. Dippold W, Steinborn A, Meyer zum Buschenfelde KH. The role of the Thomsen-Friedenreich antigen as a tumor-associated molecule. Environ Health Perspect. 1990;88:255-257.
32. Springer GF. T and Tn, general carcinoma autoantigens. Science. 1984; 224(4654):1198-1206.
33. Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A, Muschel RJ. Intravascular origin of metastasis from the proliferation of endotheliumattached tumor cells: a new model for metastasis. Nat Med. 2000; 6(1):100-102.
34. Avichezer D, Springer GF, Schechter B, Arnon R. Immunoreactivities of polyclonal and monoclonal anti-T and anti-Tn antibodies with human carcinoma cells, grown in vitro and in a xenograft model. Int J Cancer. 1997;72(1):119-127. Erratum appears in Int J Cancer. 1997; 72(5):918.
35. Choufani G, Nagy N, Saussez S, et al. The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers. Cancer. 1999;86(11):2353-2363.
36. Black RE, Levine MM, Clements ML, Hughes T, O'Donnell S. Association between O blood group and occurrence and severity of diarrhoea due to Escherichia coli. Trans R Soc Trop Med Hyg. 1987; 81(1):120-128.
37. Kurtenkov O, Klaamas K, Miljukhina L. The lower level of natural anti-Thomsen-Friedenreich antigen (TFA) agglutinins in sera of patients with gastric cancer related to ABO(H) blood-group phenotype. Int J Cancer. 1995;60(6):781-785.
38. Hansson LE, Nyrén O, Hsing AW, et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med. 1996; 335(4):242-249.
39. Rittenhouse-Olson K. JAA-F11 extending the life of mice with breast cancer. Expert Opin Biol Ther. 2007;7(7):923-928.
40. Wang WS, Lin JK, Lin TC, et al. Plasma von Willebrand factor level as a prognostic indicator of patients with metastatic colorectal carcinoma. World J Gastroenterol. 2005;11(14):2166-2170.
41. O'Donnell J, Boulton FE, Manning RA, Laffan MA. Genotype at the secretor blood group locus is a determinant of plasma von Willebrand factor level. Br J Haematol. 2002;116(2):350-356.